ZA986213B - Formulation comprising an anticonvulsant and an ion-exchange resin. - Google Patents
Formulation comprising an anticonvulsant and an ion-exchange resin.Info
- Publication number
- ZA986213B ZA986213B ZA9806213A ZA986213A ZA986213B ZA 986213 B ZA986213 B ZA 986213B ZA 9806213 A ZA9806213 A ZA 9806213A ZA 986213 A ZA986213 A ZA 986213A ZA 986213 B ZA986213 B ZA 986213B
- Authority
- ZA
- South Africa
- Prior art keywords
- anticonvulsant
- formulation
- ion
- exchange resin
- exchange
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9702793A SE9702793D0 (sv) | 1997-07-24 | 1997-07-24 | Novel formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA986213B true ZA986213B (en) | 2000-01-13 |
Family
ID=20407822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA9806213A ZA986213B (en) | 1997-07-24 | 1998-07-13 | Formulation comprising an anticonvulsant and an ion-exchange resin. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6193962B1 (es) |
| EP (1) | EP1009396B1 (es) |
| JP (1) | JP2001510798A (es) |
| AR (1) | AR018002A1 (es) |
| AT (1) | ATE214600T1 (es) |
| AU (1) | AU8371098A (es) |
| DE (1) | DE69804324T2 (es) |
| MY (1) | MY120751A (es) |
| SE (1) | SE9702793D0 (es) |
| WO (1) | WO1999004779A1 (es) |
| ZA (1) | ZA986213B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021071902A1 (en) * | 2019-10-10 | 2021-04-15 | Brillian Pharma Inc. | Micronized drug resinate-based pharmaceutical compositions and methods of preparation thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB857194A (en) * | 1957-07-05 | 1960-12-29 | Clinical Products Ltd | Therapeutic agents comprising ion-exchange resins |
| US3100738A (en) * | 1961-08-09 | 1963-08-13 | Neisler Lab Inc | Uniform release process |
| US4714620A (en) | 1986-12-12 | 1987-12-22 | Warner-Lambert Company | Soft, sugarless aerated confectionery composition |
| IL84305A (en) * | 1987-02-06 | 1992-01-15 | Fisons Corp | 2-aminoacetamide derivatives |
| AU639722B2 (en) * | 1989-10-27 | 1993-08-05 | Astra Aktiebolag | Use of arylalkylamides in the treatment of neurodegenerative diseases |
| US5188825A (en) * | 1989-12-28 | 1993-02-23 | Iles Martin C | Freeze-dried dosage forms and methods for preparing the same |
| GB9104042D0 (en) * | 1991-02-26 | 1991-04-10 | Abbott Lab | Taste-masked buflomedil preparation |
| FR2676364B1 (fr) * | 1991-05-17 | 1993-09-10 | Lafon Labor | Composition pharmaceutique a base de derives d'aminobutanone. |
| SE9103110D0 (sv) * | 1991-10-24 | 1991-10-24 | Kabi Pharmacia Ab | New drug formulation |
| JP3207494B2 (ja) * | 1992-04-02 | 2001-09-10 | ロート製薬株式会社 | 水性懸濁製剤 |
| US5455049A (en) * | 1995-01-04 | 1995-10-03 | Ascent Pharmaceuticals, Inc. | Terfenadine oral powder |
-
1997
- 1997-07-24 SE SE9702793A patent/SE9702793D0/xx unknown
-
1998
- 1998-07-13 AR ARP980103399A patent/AR018002A1/es not_active Application Discontinuation
- 1998-07-13 ZA ZA9806213A patent/ZA986213B/xx unknown
- 1998-07-17 AT AT98934112T patent/ATE214600T1/de not_active IP Right Cessation
- 1998-07-17 AU AU83710/98A patent/AU8371098A/en not_active Abandoned
- 1998-07-17 WO PCT/SE1998/001398 patent/WO1999004779A1/en active IP Right Grant
- 1998-07-17 DE DE69804324T patent/DE69804324T2/de not_active Expired - Fee Related
- 1998-07-17 EP EP98934112A patent/EP1009396B1/en not_active Expired - Lifetime
- 1998-07-17 US US09/180,134 patent/US6193962B1/en not_active Expired - Fee Related
- 1998-07-17 JP JP2000503836A patent/JP2001510798A/ja active Pending
- 1998-07-22 MY MYPI98003361A patent/MY120751A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE69804324D1 (de) | 2002-04-25 |
| ATE214600T1 (de) | 2002-04-15 |
| AR018002A1 (es) | 2001-10-31 |
| SE9702793D0 (sv) | 1997-07-24 |
| WO1999004779A1 (en) | 1999-02-04 |
| DE69804324T2 (de) | 2003-02-27 |
| AU8371098A (en) | 1999-02-16 |
| EP1009396A1 (en) | 2000-06-21 |
| JP2001510798A (ja) | 2001-08-07 |
| EP1009396B1 (en) | 2002-03-20 |
| MY120751A (en) | 2005-11-30 |
| US6193962B1 (en) | 2001-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU8333398A (en) | Injection member | |
| AU6831898A (en) | Pumping and metering device | |
| IL135295A0 (en) | 2-methyl-thieno-benzodiazepine formulation | |
| GB9901654D0 (en) | Shaft-hub unit | |
| AU7665498A (en) | Improvements in metering devices | |
| ZA966075B (en) | Protein formulation. | |
| AU6667998A (en) | Nucleic acids encoding caspase-8h and caspase-8i | |
| HK1026990A1 (en) | Encoder and decoder. | |
| EP0651101A3 (en) | Connector, assembly unit, and assembled connector comprising the same. | |
| GB9704546D0 (en) | Resin formulations | |
| EP0664580A3 (en) | Connector and adapter using such a connector. | |
| EP0618646A3 (en) | Lever operated connector. | |
| SG67523A1 (en) | Loaded ion-exchange resins their preparation and uses | |
| AU8486098A (en) | Waterproof connector and waterproofing-housing member used in the same | |
| SG70639A1 (en) | Ion-exchange resins their preparation and uses | |
| GB9725061D0 (en) | Revitalisation formulation | |
| ZA9811471B (en) | Polymer | |
| GB2321753B (en) | Metering system | |
| ZA986213B (en) | Formulation comprising an anticonvulsant and an ion-exchange resin. | |
| ZA98271B (en) | Texturing agent. | |
| GB9706957D0 (en) | Formulation | |
| GB9716454D0 (en) | Polymer | |
| GB2312069B (en) | Metering systems | |
| EP0735082A3 (en) | Phthalamide resin formulation | |
| ZA941940B (en) | Metering system. |